Ones To Watch News
Refine Search
article
Nobody can say that US biopharma Intercept Pharmaceuticals has not done all it can to reach market with a long-awaited treatment for non-alcoholic steatohepatitis (NASH). 23 June 2023
Pharmaceutical
The contract research organization (CRO) IRBM has signed a new agreement with Merck & Co to continue their collaboration in the peptide therapeutics area. 23 June 2023
Biotechnology
Switzerland-headquartered Roivant Sciences saw its shares rise 17% in pre-market trading yesterday, after it announced positive results from the chronic period of the TUSCANY-2 Phase IIb study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody. 23 June 2023
Biotechnology
Shares of US cell therapy developer Talaris Therapeutics leapt 26% to $2.77 this morning, as the company announced a proposed reverse merger. 22 June 2023
Biotechnology
Aeglea BioTherapeutics has acquired Spyre Therapeutics, a privately-held biotech advancing antibody therapeutics aimed at transforming the treatment of inflammatory bowel disease (IBD). 22 June 2023
Biotechnology
uniQure lost 40% of its market value on Wednesday. 22 June 2023
Pharmaceutical
Boston Pharmaceuticals has released positive Phase IIa results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 (FGF21) analog for the treatment of non-alcoholic steatohepatitis (NASH). 22 June 2023
Biotechnology
Promising clinical results from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington's disease (HD) lifted US pharma group PTC Therapeutics. 22 June 2023
Biotechnology
Belgo-Dutch autoimmune diseases specialist argenx can now boast that it has the first subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) to be approved by the US Food and Drug Administration (FDA). 21 June 2023
Biotechnology
Massachusetts, USA-based biotech funder and incubator Flagship Pioneering today unveiled its latest new company, Empress Therapeutics. 21 June 2023
Biotechnology
Adcendo, a Danish biotech focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has appointed Lone Ottesen its chief medical officer (CMO). 20 June 2023
Biotechnology
The US Food and Drug Administration (FDA) has slapped a clinical hold on US biotech Arcellx’ CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). 20 June 2023
Pharmaceutical
The appointment of a new chief executive at immune-mediated disease specialist Veralox Therapeutics coincides with a fresh investment of $24 million from new and existing backers. 20 June 2023
Biotechnology
Spanish genetic medicines company SpliceBio today announced the appointment of David Favre as its chief development officer (CDO). 20 June 2023
Biotechnology
China-headquartered biotech BeiGene says it is aware that Pharmacyclics has filed a complaint against BeiGene and its US subsidiary alleging that its lead product Brukinsa (zanubrutinib) infringes a patent issued on June 13, 2023, to Pharmacyclics, a subsidiary of US pharma major AbbVie. 19 June 2023
Biotechnology
Shares of Belgian biotech BioSenic were down 18.4% at 0.09 euros in early trading today, after it revealed it has suspended its interventional trial on fracture healing, using the ex-Bone-Therapeutics lead product, ALLOB. 19 June 2023
Pharmaceutical
An allergic conjunctivitis medicine developed by Aldeyra Therapeutics, reproxalap, has generated positive Phase III data in the INVIGORATE-2 trial. 16 June 2023
Biotechnology
Aiming to boost its immune-oncology pipeline, Coherus BioSciences today announced it will acquire Surface Oncology. 16 June 2023
Biotechnology
Sir Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, has stressed the importance of a new collaboration and licensing agreement to the company. 16 June 2023
Pharmaceutical
Texas, USA-based drug developer Reata Pharmaceuticals says that the US Food and Drug Administration (FDA) accepted for filing the Prior Approval Supplement (PAS) to update the drug substance specification for Skyclarys (omaveloxolone). 16 June 2023
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze